Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abbreviated, acute, adhesion, andin, answer, arm, asvascular, augment, ban, bank, Bay, bioavailability, bothin, bound, Bruno, calendar, CEEF, CEFF, cessation, cetuximab, choose, confirmatory, cornea, corneal, deliver, differentiated, disable, disabling, disgorgement, dissemination, durable, effort, eighteen, element, encouraging, entity, epidemiology, executory, exert, expansion, eyedrop, false, fashion, feasible, Fickling, formedwithin, formulary, fosbretabulin, front, glaucoma, greatest, havealready, Hill, inactivation, inclusion, infusion, Injectable, injected, Intracel, invention, ion, issuedEITF, journalBlood, kinase, Kingsbridge, leaflet, length, lethal, letter, leukemia, licence, lift, lost, lt, malignancy, middle, misleading, mobilizing, moiety, molecule, negotiated, negotiating, nonrefundable, occlusion, ofEITF, online, overwhelming, parallel, partner, Patricia, percent, pharmacoeconomic, pharmacy, pivotal, platinum, postmarket, PREA, preceing, prematurity, premium, primate, prolonged, proportion, rabbit, recovered, refractory, registry, regression, resale, responded, restitution, restoration, reversible, rodent, Roy, sarcoma, Schwieterman, secret, sickle, Simon, SPA, straight, strictly, sublicense, subpopulation, subset, supposed, television, thousand, tier, topreventthe, tyrosine, unable, unexpected, unsuccessful, unvalidated, vein, version, volume, Walicke, whichever, withintravenousZYBRESTAT, ZYBRESTAT, ZYBRESTATtm
Removed:
Acid, activated, administering, afforded, aim, angiogenic, anniversary, Antineoplastic, arose, blurring, cancel, cervical, charged, cisplatin, composition, compounded, concurrently, consolidated, corrected, counteracting, creator, defense, degenerative, description, destruction, Detroit, disciplined, Disodium, distortion, doxorubicin, elongation, Elucidation, enhancing, Ernst, essentially, Ester, evidenced, favor, Ford, functionally, generation, gleaned, hemorrhaging, hereditary, Histidine, immune, immunosuppression, importance, inactive, incurring, infiltrated, injunctive, investigating, involving, Isolation, Josephine, leak, LLP, loan, matter, measurable, mix, monetary, Mono, multimodality, open, organic, parent, participant, past, permitted, Pittsburgh, platform, portfolio, preferred, presence, proliferating, radiolabeled, relate, relief, repaid, repeat, scarring, scheduled, scope, secondary, secrecy, sixteen, structurally, synthesizing, thereof, traditional, transfer, Tromethamine, undergoing, underway, unfavorable, unpaid, unwanted, virtually, wAMD, wet, Young
Filing tables
Filing exhibits
Related press release
OTLC similar filings
Filing view
External links
Exhibit 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 333-128528, 333-106307 and 333-109433 and Form S-8 Nos. 333-05787, 333-92747, 333-32958, 33-117083, 333-84870, 333-84872 and 333-126636) of OXiGENE, Inc. and in the related prospectuses of our reports dated March 13, 2008, with respect to the financial statements of OXiGENE, Inc., and the effectiveness of internal control over financial reporting of OXiGENE, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2007.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 13, 2008
March 13, 2008